Last reviewed · How we verify

NCT02971254

The Effects of Inhalational Anaesthetics in Cognitive Functions in Down Syndrome Patients

Completed Phase 2 Last updated 9 June 2020
What this trial tests

Phase 2 trial testing Sevoflurane in Down Syndrome in 39 participants. Completed in 30 May 2019.

Timeline
1 December 2016
Primary endpoint
6 January 2019
30 May 2019

Quick facts

Lead sponsorAsklepieion Voulas General Hospital
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment39
Start date1 December 2016
Primary completion6 January 2019
Estimated completion30 May 2019
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

Asklepieion Voulas General Hospital

Who can join

Adults 16 to 75, any sex, with Down Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recovery of the cognitive functions and recovery features after general anaesthesia in Down syndrome patients. A comparison of Sevoflurane and Desflurane.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The impact of inhalation anesthetics on early postoperative cognitive function and recovery characteristics in Down syndrome patients: a randomized, double - blind study.
    Gkliatis E, Makris A, Staikou C. · · 2021 · cited 2× · PMID 34535086 · DOI 10.1186/s12871-021-01447-x

Verify or expand the search:

Other trials of Sevoflurane

Trials testing the same drug.

Other recruiting trials for Down Syndrome

Currently open trials in the same condition.

Other Asklepieion Voulas General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02971254.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing